In addition to druggable pathways, characterizing SSVs in DLBCL cell lines also identified the key genes FCGR3A, FLT4, and CYP2B6, whose mutations would affect the drug response in the patients. Here, CYP2B6 is linked to diffuse large B-cell lymphoma.